Abstract
Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the biological events underlying the development of these diseases is needed to identify new targets and generate effective novel therapies. MicroRNAs (miRNAs), which are single strand, 20- nucleotide, non-coding RNAs, are key regulators of gene expression and have been reported to exert transcriptional control in multiple myeloma and other plasma cell dyscrasias. miRNAs are now recognized to play a role in many key areas such as cellular proliferation, differentiation, apoptosis and stress response. Substantial advances have been made in recent years in terms of our understanding of the biological role of miRNAs in this complex and diverse set of disorders, leading to the new information, which is of diagnostic and prognostic relevance.
Keywords: MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstrom’s macroglobulinemia.
MicroRNA
Title:The Role of miRNAs in Plasma Cell Dyscrasias
Volume: 2 Issue: 3
Author(s): Siobhan Glavey, Salomon Manier, Antonio Sacco, Giuseppe Rossi, Irene M. Ghobrial and Aldo M. Roccaro
Affiliation:
Keywords: MGUS, miRNA, multiple myeloma, plasma cell, regulation, waldenstrom’s macroglobulinemia.
Abstract: Plasma cell dyscrasias are a group of related disorders that have in common the clonal proliferation of plasma cells with resultant production of a monoclonal immunoglobulin that can be detected on serum protein electrophoresis (M-spike). This term incorporates the Plasma Cell Neoplasms along with other related disorders that are not considered malignant. Comprehensive genomic studies have greatly advanced our understanding of the genetic complexity of these diseases in recent years, however they continue to be considered incurable with a highly heterogeneous phenotype. It is clear that a deeper level of knowledge of the biological events underlying the development of these diseases is needed to identify new targets and generate effective novel therapies. MicroRNAs (miRNAs), which are single strand, 20- nucleotide, non-coding RNAs, are key regulators of gene expression and have been reported to exert transcriptional control in multiple myeloma and other plasma cell dyscrasias. miRNAs are now recognized to play a role in many key areas such as cellular proliferation, differentiation, apoptosis and stress response. Substantial advances have been made in recent years in terms of our understanding of the biological role of miRNAs in this complex and diverse set of disorders, leading to the new information, which is of diagnostic and prognostic relevance.
Export Options
About this article
Cite this article as:
Glavey Siobhan, Manier Salomon, Sacco Antonio, Rossi Giuseppe, Ghobrial M. Irene and Roccaro M. Aldo, The Role of miRNAs in Plasma Cell Dyscrasias, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/2211536602666131126002144
DOI https://dx.doi.org/10.2174/2211536602666131126002144 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Hematological Malignancies and Pregnancy. A Brief Review
Reviews on Recent Clinical Trials T Cell Suicide Gene Therapy to Aid Haematopoietic Stem Cell Transplantation
Current Gene Therapy Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances
Current Gene Therapy The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology De Novo DNMTs and DNA Methylation: Novel Insights into Disease Pathogenesis and Therapy from Epigenomics
Current Pharmaceutical Design Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Subject Index To Volume 1
Recent Patents on Anti-Cancer Drug Discovery Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets P53 Mdm2 Inhibitors
Current Pharmaceutical Design Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Current Developments in the Synthesis and Biological Activity of Aza-C-Nucleosides:Immucillins and Related Compounds
Current Medicinal Chemistry Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Association of Chemotherapy and Radiotherapy in Squamous Cell Carcinoma of Anal Canal
Current Drug Therapy